Native asparaginase from E. coli and Erwinia chrysanthemi was approved by the US Food and Drug Administration (FDA) in 1994 and 2011, respectively, for use in patients with acute lymphoblastic leukemia (ALL). This evidence concerns the gene ASPG and acute lymphoblastic leukemia.